• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care
    Get the next $PDEX alert in real time by email

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.

    Quarter Ended June 30, 2024

    Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $2.0 million in sales of new units to that same customer. Gross profit for the three months ended June 30, 2024 increased $729,000, or 22%. Although gross profit increased, our gross margin decreased from 32% for the three months ended June 30, 2023, to 27% for the three months ended June 30, 2024, due to continued price pressures and increased indirect labor in our operations group to manage our growth.

    Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2024, remained relatively flat at $1.7 million, compared to $1.8 million for the prior fiscal year's corresponding quarter. While these total operating expense amounts have remained flat, we reduced general and administrative expenses by $182,000 and increased engineering expenses by $141,000 for the quarter ended June 30, 2024, compared to the corresponding quarter in 2023. The decrease in general and administrative expenses is a result of reduced equity compensation expenses due to employee forfeitures and the increase in engineering relates to a higher proportion of sustaining engineering expenses as opposed to billable customer contract expenses.

    Our operating income for the quarter ended June 30, 2024, increased $742,000, or 46%, to $2.4 million compared to $1.6 million for the prior fiscal year's corresponding quarter. The increase reflects our increased sales and gross profit, as described above.

    Net income for the quarter ended June 30, 2024, increased slightly by $86,000 to $1.6 million, or $0.46 per diluted share, compared to $1.5 million, or $0.42 per diluted share, in the corresponding quarter in 2023. The difference in the growth rate of net income and operating income is primarily due to unrealized gains and losses of investments. In the current quarter, operating income increased 46% over the corresponding quarter of the prior fiscal year compared to the slight increase in net income for the same period.

    Year Ended June 30, 2024

    Net sales for the fiscal year ended June 30, 2024 increased $7.8 million, or 17%, to $53.8 million from $46.0 million for the fiscal year ended June 30, 2023, due primarily to increases in revenue from our largest customer. Specifically, the increase relates to a $3.6 million increase in repair revenue as well as an increase of $3.5 million in sales of new units to that same customer.

    Gross profit for the fiscal year ended June 30, 2024, increased $1.8 million, or 14%, to $14.5 million compared to $12.7 million for fiscal 2023.

    Operating expenses (which include selling, general and administrative, and research and development expenses) for the fiscal year ended June 30, 2024, increased 6% to $7.4 million from $7.0 million in the prior fiscal year. The increase relates primarily to an increase in research and development costs because in fiscal 2024 our expenditures related primarily to sustaining engineering activities rather than billable customer projects which are reclassified to cost of sales.

    Our operating income for the year ended June 30, 2024, increased $1.4 million, or 25%, to $7.2 million compared to $5.8 million for the prior fiscal year's corresponding quarter. The increase reflects our increased sales and gross profit, as described above.

    Net income for the fiscal year ended June 30, 2024, was $2.1 million, or $0.60 per diluted share, compared to $7.1 million, or $1.95 per diluted share, for fiscal 2023. Our net income for the year ended June 30, 2024, contains unrealized losses on our marketable equity investments of $4.1 million while our net income for the year ended June 30, 2023, contains unrealized gains on our marketable equity investments of $3.9 million. The difference in the growth rate of net income and operating income is primarily due to unrealized gains and losses of investments. In the current fiscal year operating income increased 25% over the prior fiscal year, compared to the 70% decrease in net income for the same period. All of our investments are recorded at estimated fair value, and the valuation can be highly volatile.

    CEO Comments

    "We are very pleased with our performance including increasing sales and an increase of $1.4 million in operating income," said the Company's President and Chief Executive Officer Richard L. ("Rick") Van Kirk. "While this fiscal year included the challenges of transitioning to a multiple-facility operation, we continued to grow the business. I remain grateful to the entire Pro-Dex team for their ongoing efforts and teamwork."

    Mr. Van Kirk continued, "Additionally, we are excited to announce that we hired a new Director of Operations in the first quarter of fiscal 2025, Mr. Jawahar Garg, who has extensive manufacturing operations and supply chain experience to assist our team to continue on our growth trajectory."

    About Pro-Dex, Inc.:

    Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adoptive torque-limiting software and proprietary sealing solutions which appeal to our customers, primarily medical device distributors. Pro-Dex also sells rotary air motors. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's website at www.pro-dex.com.

    Statements herein concerning the Company's plans, growth and strategies may include "forward-looking statements" within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance (including, but not limited to, prospects for future growth) as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business risks of the Company set forth in the Company's filings with the Securities and Exchange Commission.

    (tables follow)

    PRO-DEX, INC. AND SUBSIDIARY
    CONSOLIDATED BALANCE SHEETS
    (In thousands, except share data)

    June 30,

    2024

    2023

    ASSETS

    Current assets:

    Cash and cash equivalents

    $

    2,631

    $

    2,936

    Investments

    4,217

    1,134

    Accounts receivable

    13,887

    9,952

    Deferred costs

    262

    494

    Inventory

    15,269

    16,167

    Prepaid expenses

    345

    296

    Total current assets

    36,611

    30,979

    Land and building, net

    6,155

    6,249

    Equipment and improvements, net

    5,024

    5,079

    Right of use asset, net

    1,473

    1,872

    Intangibles, net

    54

    81

    Deferred income taxes, net

    1,555

    -

    Investments

    1,563

    7,521

    Other assets

    42

    42

    Total assets

    $

    52,477

    $

    51,823

    LIABILITIES AND SHAREHOLDERS' EQUITY

    Current liabilities:

    Accounts payable

    $

    4,513

    $

    2,261

    Accrued liabilities

    3,359

    3,135

    Income taxes payable

    632

    453

    Deferred revenue

    14

    -

    Notes payable

    4,374

    3,827

    Total current liabilities

    12,892

    9,676

    Non-current liabilities:

    Lease liability, net of current portion

    1,182

    1,638

    Deferred income taxes, net

    -

    8

    Notes payable, net of current portion

    7,536

    8,911

    Total non-current liabilities

    8,718

    10,557

    Total liabilities

    21,610

    20,233

    Commitments and Contingencies:

    Shareholders' equity:

    Common stock, no par value, 50,000,000 shares authorized; 3,363,412 and 3,545,309 shares issued and outstanding at June 30, 2024 and 2023, respectively

    3,917

    6,767

    Retained earnings

    26,950

    24,823

    Total shareholders' equity

    30,867

    31,590

    Total liabilities and shareholders' equity

    $

    52,477

    $

    51,823

    PRO-DEX, INC. AND SUBSIDIARY
    CONSOLIDATED INCOME STATEMENTS
    (In thousands, except per share data)

    Three Months Ended
    June 30,
    (Unaudited)

    Years Ended
    June 30,

    2024

    2023

    2024

    2023

    Net sales

    $

    15,025

    $

    10,639

    $

    53,844

    $

    46,087

    Cost of sales

    10,936

    7,279

    39,293

    33,338

    Gross profit

    4,089

    3,360

    14,551

    12,749

    Operating expenses:

    Selling expenses

    37

    9

    117

    155

    General and administrative expenses

    864

    1,046

    4,072

    4,028

    Research and development costs

    836

    695

    3,189

    2,804

    Total operating expenses

    1,737

    1,750

    7,378

    6,987

    Operating income

    2,352

    1,610

    7,173

    5,762

    Interest expense

    (150

    )

    (145

    )

    (558

    )

    (533

    )

    Unrealized gain (loss) on investments

    (340

    )

    492

    (4,125

    )

    3,899

    Gain on sale of investments

    -

    -

    -

    6

    Interest and dividend income

    68

    58

    144

    294

    Income before income taxes

    1,930

    2,015

    2,634

    9,428

    Income tax expense

    343

    514

    507

    2,354

    Net income

    $

    1,587

    $

    1,501

    $

    2,127

    $

    7,074

    Basic & Diluted income per share:

    Basic net income per share

    $

    0.47

    $

    0.42

    $

    0.61

    $

    1.98

    Diluted net income per share

    $

    0.46

    $

    0.42

    $

    0.60

    $

    1.95

    Weighted average shares outstanding:

    Basic

    3,400,767

    3,545,309

    3,498,807

    3,571,044

    Diluted

    3,473,167

    3,610,109

    3,571,207

    3,636,944

    PRO-DEX, INC. AND SUBSIDIARY
    CONSOLIDATED STATEMENTS OF CASH FLOWS
    (In thousands)

    Years Ended June 30,

    2024

    2023

    CASH FLOWS FROM OPERATING ACTIVITIES:

    Net income

    $

    2,127

    $

    7,074

    Adjustments to reconcile net income to net cash provided by operating activities:

    Depreciation and amortization

    1,160

    857

    Unrealized (gain) loss on marketable equity investments

    4,125

    (3,899

    )

    Gain on sale of investments

    -

    (6

    )

    Non-cash lease recovery

    (17

    )

    (2

    )

    Amortization of loan fees, net

    (13

    )

    12

    Share-based compensation

    605

    766

    Deferred income taxes

    (1,563

    )

    264

    Changes in operating assets and liabilities:

    Accounts receivable

    (3,935

    )

    5,432

    Deferred costs

    232

    216

    Inventory

    898

    (3,489

    )

    Prepaid expenses

    (49

    )

    494

    Accounts payable and accrued expenses

    2,436

    (1,153

    )

    Deferred revenue

    14

    (1,013

    )

    Income taxes payable

    179

    (91

    )

    Net cash provided by operating activities

    6,199

    5,462

    CASH FLOWS FROM INVESTING ACTIVITIES:

    Purchases of equipment and improvements

    (983

    )

    (974

    )

    Proceeds from sale of investments

    -

    89

    Investment in Monogram

    (1,250

    )

    -

    Net cash used in investing activities

    (2,233

    )

    (885

    )

    CASH FLOWS FROM FINANCING ACTIVITIES:

    Principal payments on notes payable

    (4,816

    )

    (6,093

    )

    Borrowing from Minnesota Bank & Trust, net of loan origination fees

    4,000

    5,284

    Repurchases of common stock

    (3,505

    )

    (1,547

    )

    Payments of employee taxes on net issuance of common stock

    -

    (223

    )

    Proceeds from exercise of stock options and ESPP contributions

    50

    89

    Net cash used in financing activities

    (4,271

    )

    (2,490

    )

    Net increase (decrease) in cash and cash equivalents

    (305

    )

    2,087

    Cash and cash equivalents, beginning of year

    2,936

    849

    Cash and cash equivalents, end of year

    $

    2,631

    $

    2,936

    Contact: Richard L. Van Kirk, Chief Executive Officer
    (949) 769-3200

    SOURCE: Pro-Dex, Inc.



    View the original press release on accesswire.com

    Get the next $PDEX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PDEX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PDEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Philp Katrina Marie Kramer was granted 3,100 shares, increasing direct ownership by 45% to 2,900 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/24/25 4:00:02 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Chief Executive Officer Van Kirk Richard Lee Jr covered exercise/tax liability with 72 shares, decreasing direct ownership by 0.07% to 99,707 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/21/25 6:46:37 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Director Swenson Nicholas John was granted 1,000 shares, increasing direct ownership by 1% to 97,613 units (SEC Form 4)

    4 - PRO DEX INC (0000788920) (Issuer)

    11/21/25 6:45:52 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Third Quarter And Nine-Month Results

    IRVINE, CA / ACCESSWIRE / May 2, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 third quarter ended March 31, 2024. The Company also filed its Quarterly Report on Form 10-Q for the third quarter of fiscal year 2024 with the Securities and Exchange Commission today.Quarter Ended March 31, 2024Net sales for the three months ended March 31, 2024, increased $1.2 million, or 9%, to $14.3 million from $13.1 million for the three months ended March 31, 2023, due primarily to an increase in medical device product revenue of $2.8 million offset by a decrease in non-recurring engineering and repair revenue of $736,000 and $635,000 respectively.Gross profit for

    5/2/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    SEC Filings

    View All

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    12/19/25 4:00:23 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    11/21/25 4:01:39 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - PRO DEX INC (0000788920) (Filer)

    10/30/25 4:05:26 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Pro-Dex Inc.

    SC 13D - PRO DEX INC (0000788920) (Filed by)

    10/17/23 5:00:05 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed

    SC 13D/A - PRO DEX INC (0000788920) (Subject)

    2/22/21 4:47:58 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    $PDEX
    Financials

    Live finance-specific insights

    View All

    PRO-DEX, INC. Announces Fiscal 2025 First Quarter Results

    IRVINE, CA / ACCESSWIRE / October 31, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2025 first quarter ended September 30, 2024. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2025 with the Securities and Exchange Commission today.Quarter Ended September 30, 2024Net sales for the three months ended September 30, 2024, increased $3.0 million, or 25%, to $14.9 million from $11.9 million for the three months ended September 30, 2023. The increase is driven primarily by $1.1 million in increased repairs of the surgical handpiece we sell to our largest customer as well as the shipment of that customer's next gene

    10/31/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 Fourth Quarter and Full-Year Results

    IRVINE, CA / ACCESSWIRE / September 5, 2024 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 fourth quarter and full-year ended June 30, 2024.Quarter Ended June 30, 2024Net sales for the three months ended June 30, 2024 increased $4.4 million, or 41%, to $15.0 million from $10.6 million for the three months ended June 30, 2023, due primarily to increased revenue in the amount of $3.4 million from our largest customer. Specifically, the increase relates to a $1.4 million increase in repair revenue related to the enhanced repair program we began last fiscal year to refurbish the orthopedic handpiece we sell to our largest customer, as well as an increase of $

    9/5/24 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care

    Pro-Dex, Inc. Announces Fiscal 2024 First Quarter Results

    IRVINE, CA / ACCESSWIRE / November 2, 2023 / PRO-DEX, INC. (NASDAQ:PDEX) today announced financial results for its fiscal 2024 first quarter ended September 30, 2023. The Company also filed its Quarterly Report on Form 10-Q for the first quarter of fiscal year 2024 with the Securities and Exchange Commission today.Net sales for the three months ended September 30, 2023, increased $851,000, or 8%, to $11.9 million from $11.1 million for the three months ended September 30, 2022. The increase is driven primarily by $1.8 million in increased repairs of the surgical handpiece we sell to our largest customer offset primarily by a decrease of $0.7 million in sales of our NRE & proto-type offerings

    11/2/23 4:00:00 PM ET
    $PDEX
    Medical/Dental Instruments
    Health Care